<DOC>
	<DOCNO>NCT01730508</DOCNO>
	<brief_summary>This multicenter , prospective , observational study evaluate use clinical practice efficacy safety Pegasys ( peginterferon alfa-2a ) Chinese participant HBeAg negative chronic hepatitis B . Participants receive Pegasys accord local label follow duration treatment one year cessation treatment .</brief_summary>
	<brief_title>An Observational Study Pegasys ( Peginterferon Alfa-2a ) Chinese Patients With HBeAg Negative Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age Treatment Pegasys accord label standard clinical practice HBeAg negative serologically proven chronic hepatitis B without cirrhosis Serum alanine aminotransferase ( ALT ) &gt; upper limit normal ( ULN ) &lt; /= 10 x ULN Hepatitis B Virus ( HBV ) DNA &gt; /= 2000 IU/mL Contraindications Pegasys detail label Coinfection hepatitis A , hepatitis C HIV Pregnant lactate woman Participants receive concomitant therapy telbivudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>